PTN

4.5607.51%
JK

John K. A. Prendergast

Independent Non-Executive Chairman

Dr. John K. A. Prendergast, Ph.D., had been an Independent Chairman of Recce Pharmaceuticals Ltd since July 9, 2019 and serves as its Executive Chairman of the Board since September 5, 2022. Dr. Prendergast is a President, Chief Executive Officer and Principal of Summercloud Bay Inc., since 1993. Dr. Prendergast serves as an Executive Chairman and Chief Executive Officer of Antyra, Inc. Dr. Prendergast is the Co-Founder of Palatin Technologies Inc. and has been its Independent Non-Executive Chairman since June 14, 2000. Dr. Prendergast has been an Independent Non-Executive Director of Recce Pharmaceuticals Ltd. since April 23, 2018. He served as the Chief Executive Officer of AVAX Technologies, Inc. since October 16, 2009. He is a Co-Founder of AVAX Technologies Inc. and served as its Executive Chairman since November 2003. He is a Co-founder of Atlantic Pharmaceuticals Inc., Avigen, Inc., Xenometrix, Inc., Ingenex Inc., Optex Ophthamologics Inc., Gemini Genetherapies, Inc. and Channel Therapeutics, Inc. Dr. Prendergast is a venture capitalist, who has been involved in the founding, financing and corporate development of early to mid-stage biotechnology companies for over the past 10 years. He served as Vice President and Treasurer of Avigen, Inc., from December 1992 to March 1996. He served as Managing Director of Paramount Capital Investments LLC and The Castle Group Ltd. from October 1991 to December 1997. Dr. Prendergast served as an Investment Banker in the Corporate Finance division of D.H. Blair & Co., Inc. from May 1991 to September 1991. He was Independent Lead Director of Scorpius Holdings, Inc. (formerly known as NightHawk Biosciences, Inc.) (formerly known as Heat Biologics, Inc.) since September 2016 and was its Director since April 2016 until 2025. Dr. Prendergast joined the Scorpius Holdings, Inc. on April 21, 2016. He has been an Independent Director at Palatin Technologies Inc., since August 1996 and Channel Therapeutics, Inc. since August 1994. He serves as the Co-founder and Executive Chairman of Nejo Inc. He serves as a Director of Atlantic Pharmaceuticals Inc., Ingenex Inc., Optex Ophthamologics Inc. and Gemini Genetherapies, Inc. He served as Director of Avigen, Inc., since December 1992 and served as its Lead Independent Director since September 2004. He served as a Director of MediciNova, Inc. from September 2004 to September 26, 2011. Dr. Prendergast served as Director of Xenometrix, Inc. and AVAX Technologies Inc. since July 1996. From 1988 to 1991, he held Post-Doctoral Fellowships in the Department of Biochemistry and Molecular Biology, at Harvard University and the Institute for Blood Diseases at L'Hospital St. Louis in Paris, France. Dr. Prendergast received his M.Sc. and Ph.D. degrees from the University of New South Wales, Sydney, Australia and his C.S.S. in Administration and Management from Harvard University.

Positions